Drug Discovery & Development Insights by OmicsX
No Result
View All Result
  • Login
  • Register
  • Home
  • Channels
  • Startups
  • Pipeline
  • Drug Targets
  • Bio Partnering
  • Opinion
PRICING
SUBSCRIBE
  • Home
  • Channels
  • Startups
  • Pipeline
  • Drug Targets
  • Bio Partnering
  • Opinion
No Result
View All Result
Drug Discovery & Development Insights by OmicsX
No Result
View All Result

Global Cancer Targeting Small Molecule Kinase Inhibitors in Clinical Development – 2021

Insights on 300+ Clinical Stage Kinase Inhibitors in Active Development

Team OmicsX by Team OmicsX
July 3, 2021
in Drug Targets, Kinase, Oncology, Pipeline, Small Molecules
Home Oncology Small Molecules Kinase
501
SHARES
1.4k
VIEWS
Share on FacebookShare on Twitter

First cancer targeting tyrosine kinase inhibitor imatinib was approved to enter the market by the US Food and Drug Administration (FDA) in 2001, since then an increasing number of small-molecule targeted drugs have been developed and approved for the treatment of cancer. By the end of June 2021, worldwide 96 small-molecule targeted antitumor drugs have been approved by the US FDA and the National Medical Products Administration (NMPA) of China, which majorly includes 73 kinase Inhibitors, beside other including Epigenetic Inhibitors, inhibitors of BCL-2, hedgehog pathway, proteasome, and PARP.

Global Oncology Intelligence Global Oncology Intelligence Global Oncology Intelligence

Beside Cancer, nearly 14 other disease targeting small molecule Kinase Inhibitors were also approved worldwide during the same time period, thus making total tally to 87 approved kinase Inhibitors.

Despite great progress, small-molecule targeted anti-cancer drugs still face many challenges, such as a low response rate and drug resistance. This article carefully summarizes the approved cancer kinases inhibitors.

Jump to section

1. Check Also :-

  • 1. Check Also :-
  • 2. List of 300 Kinases Inhibitors in Clinical Development
  1. Upcoming Kinases Approvals their Competition & Market Size
  2. Kinases in Clinical Development – 200 Molecules / 200 Companies
  3. Kinases in Preclinical Development – 200 Molecules / 200 Companies
  4. Emerging Preclinical Stage Small Molecule Targeting Drug Developers. (131 Companies)
  5. Approved Non- Cancer Targeting Small Molecule Kinases.
Jump to section

1. Check Also :-

  • 1. Check Also :-
  • 2. List of 300 Kinases Inhibitors in Clinical Development
Page 1 of 2
Previous 12 Next
Previous Post

Targeted Cancer Therapies in Development – Small Molecules

Next Post

Global Cancer Targeting Small Molecule Kinase Inhibitors in Preclinical Development – 2021

Next Post

Global Cancer Targeting Small Molecule Kinase Inhibitors in Preclinical Development - 2021

Drug Discovery & Development Insights by OmicsX

Mapping Bio-Innovations

updated.. easy.. precise... complete...

Presenting filtered comprehensive information. Gain more insights on emerging bio-business, frame strategies, grow faster & better connect with biological science community.

LEARN MORE »

  • Trending
  • Comments
  • Latest
Approved Monoclonal Antibodies for Cancer Treatment

Approved Monoclonal Antibodies for Cancer Treatment

July 1, 2021
Worldwide 73 Approved Oncology Targeting Small Molecule Kinase Inhibitors

Worldwide 73 Approved Oncology Targeting Small Molecule Kinase Inhibitors

June 30, 2021

Small Molecule Kinase Inhibitors – Preclinical Drug Developers Profiles

July 1, 2021

Global Cancer Targeting Small Molecule Kinase Inhibitors in Preclinical Development – 2021

July 3, 2021
Approved Monoclonal Antibodies for Cancer Treatment

Approved Monoclonal Antibodies for Cancer Treatment

1
Cancer Targeting Clinical Stage Monoclonal Antibodies in Active Development – 2021

Cancer Targeting Clinical Stage Monoclonal Antibodies in Active Development – 2021

1
Cancer Targeting Pre-Clinical Stage Monoclonal Antibodies in Active Development – 2021

Cancer Targeting Pre-Clinical Stage Monoclonal Antibodies in Active Development – 2021

1
Cancer Targeting Pre-Clinical Stage Monoclonal Antibodies in Active Development – 2021

Cancer Targeting Clinical Stage Bispecific Antibodies in Active Development – 2021

1
Approved Small Molecule Kinase (Non-Oncology) Inhibitors

test onco deals and alliance

May 27, 2022

Targeted Cancer Therapies in Development – Antibodies

July 1, 2021

Cancer Targeting Small Molecule Epigenetic Drugs in Development – An Overview

May 27, 2022

Global Cancer Targeting Small Molecule Epigenetic Inhibitors – 2021

June 30, 2021

Developed by OmicsX. The entirety of this site is protected by copyright © 2010–2021 HH BioTechnologies Private Ltd.

No Result
View All Result
  • Home
  • Subscription
  • Category
    • Opinion
    • Tech
  • Landing Page
  • Buy JNews
  • Support Forum
  • Pre-sale Question
  • Contact Us

Developed by OmicsX. The entirety of this site is protected by copyright © 2010–2021 HH BioTechnologies Private Ltd.

Welcome Back!

Login to your account below

Forgotten Password? Sign Up

Create New Account!

Fill the forms below to register

*By registering into our website, you agree to the Terms & Conditions and Privacy Policy.
All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In
This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.
Are you sure want to unlock this post?
Unlock left : 0
Are you sure want to cancel subscription?

Dynamic title for modals

Are you sure?

Please confirm deletion. There is no undo!